View in EDS

Levodopa-carbidopa intestinal gel for advanced Parkinson's disease: Impact of LRRK2 and GBA1 mutations.

Saved in:

Bibliographic Details
Title:	Levodopa-carbidopa intestinal gel for advanced Parkinson's disease: Impact of LRRK2 and GBA1 mutations.
Authors:	Thaler, Avner^1,2,3,4 (AUTHOR) avnert@tlvmc.gov.il, Anis, Saar^1,5,6 (AUTHOR), Ponger, Penina^1,2 (AUTHOR), Fay-Karmon, Tsviya^1,5,6,7 (AUTHOR), Livneh, Vered^1,2 (AUTHOR), Faust-Socher, Achinoam^1,2 (AUTHOR), Greenbaum, Lior^1,7,8 (AUTHOR), Reiner, Johnathan^1,9 (AUTHOR), Hilel, Ariela² (AUTHOR), Shabtai, Hertzel² (AUTHOR), Alcalay, Roy N.^1,2,10 (AUTHOR), Djaldetti, Ruth^1,9 (AUTHOR), Hassin-Baer, Sharon^1,5,6,7 (AUTHOR), Ezra, Adi² (AUTHOR), Mirelman, Anat^1,3,4 (AUTHOR), Giladi, Nir^1,2,4 (AUTHOR), Gurevich, Tanya^1,2,4 (AUTHOR)
Source:	Parkinsonism & Related Disorders. Oct2024, Vol. 127, pN.PAG-N.PAG. 1p.
Database:	Academic Search Ultimate

Description
ISSN:	13538020
DOI:	10.1016/j.parkreldis.2024.107115